Cybin (HELP) Total Non-Current Liabilities (2021 - 2025)
Cybin (HELP) posted quarterly Total Non-Current Liabilities of $28.9 million for Q3 2025, up 294.89% year-on-year from $7.3 million in Q3 2024, and down 35.08% on a QoQ basis from $44.5 million in Q2 2025.
Cybin (HELP) Total Non-Current Liabilities (2021 - 2025) Analysis & Trends
Cybin (HELP) has reported Total Non-Current Liabilities for 5 consecutive years, with $28.9 million the latest figure, recorded in Q3 2025.
- Quarterly Total Non-Current Liabilities rose 294.89% year-over-year to $28.9 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $28.9 million (up 294.89% YoY) and the FY2024 annual result came in at -$11.5 million, changed N/A from the prior year.
- Total Non-Current Liabilities declined to $28.9 million in Q3 2025 per HELP's latest filing, from $44.5 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for HELP reached as high as $44.5 million in Q2 2025 and fell as low as -$15.2 million in Q2 2024.
- A 5-year average of $72554.6 and a median of -$4.1 million in 2021 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities slumped 33253.61% — and 2025, when it jumped 392.28%.
- Year by year, Total Non-Current Liabilities stood at -$4.4 million in 2021, then retreated by 9.02% to -$4.8 million in 2022, then jumped by 100.64% to $30850.5 in 2023, then sank by 33253.61% to -$10.2 million in 2024, then surged by 382.44% to $28.9 million in 2025.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $28.9 million, $44.5 million, and -$10.2 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Cybin | 28.04 Mn | 28.04 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 28.89 Mn |
| Jun 30, 2025 | 44.50 Mn |
| Dec 31, 2024 | -10.23 Mn |
| Sep 30, 2024 | -14.82 Mn |
| Jun 30, 2024 | -15.23 Mn |
| Mar 31, 2024 | -11.53 Mn |
| Dec 31, 2023 | 30,850.49 |
| Sep 30, 2023 | -3.78 Mn |
| Jun 30, 2023 | 173,457.42 |
| Feb 28, 2023 | 226,867.54 |
| Dec 31, 2022 | -4.79 Mn |
| Sep 30, 2022 | -4.90 Mn |
| Dec 31, 2021 | -4.40 Mn |
| Sep 30, 2021 | -4.47 Mn |
| Jun 30, 2021 | 626,415.91 |
| Mar 31, 2021 | 864,368.44 |